Imara Inc Stock

$21.91

11.44% yesterday

Nasdaq, Jun 13, 10:00 pm CET

ISIN

US45249V1070

Symbol

ELVN

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Imara Inc Stock price

$21.91

-133.73 85.92% 5Y

Nasdaq, Closing price Fri, Jun 13 2025

+2.25 11.44%

ISIN

US45249V1070

Symbol

ELVN

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Market capitalization	$964.70m
Enterprise Value	$675.14m
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
P/B ratio (TTM) P/B ratio	3.34
Revenue (TTM) Revenue	$0.00
EBIT (operating result TTM) EBIT	$-110.26m
Free Cash Flow (TTM) Free Cash Flow	$-74.00m
Cash position	$289.56m
EPS (TTM) EPS	$-1.89
P/E forward	negative
P/S forward	135,055.30
EV/Sales forward	94,517.71
Short interest	20.70%

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

Get Started for Free Today

Imara Inc Stock Analysis

Unlock Scores for Free

??

9 Analysts have issued a Imara Inc forecast:

9x Buy

100%

More details on Analyst Estimates Including Price Targets

9 Analysts have issued a Imara Inc forecast:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from Imara Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	- -	- 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	25 25	20% 20% -
- Research and Development Expense	86 86	18% 18% -
EBITDA	-110 -110	18% 18% -
- Depreciation and Amortization	0.31 0.31	0% 0% -
EBIT (Operating Income) EBIT	-110 -110	18% 18% -
Net Profit	-95 -95	19% 19% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Imara Inc Stock News

Neutral

PRNewsWire

●

about 12 hours ago

Enliven Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

BOULDER, Colo. , June 13, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that it has priced its previously announced underwritten public offering of 8,394,737 shares of its common stock at a price to the public of $19.66 pe...

Neutral

PRNewsWire

●

about 16 hours ago

Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

BOULDER, Colo. , June 13, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that it has commenced an underwritten public offering of $200 million of shares of its common stock and, in lieu of common stock to investors who so c...

Neutral

PRNewsWire

●

about 16 hours ago

Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML at EHA 2025 Congress

Reported cumulative MMR rate of 47% (25 of 53) by 24 weeks with 32% (13 of 41) of patients achieving MMR by 24 weeks, which continues to compare favorably to precedent Phase 1 trials of approved BCR::ABL1 TKIs ELVN-001 continues to demonstrate a favorable safety and tolerability profile across all dose levels with 90 patients enrolled and a median treatment duration of ~29 weeks at cutoff Enliv...

More Imara Inc News

Company Profile

Imara, Inc. engages in the development and commercialization of novel therapeutics to treat patients suffering from hemoglobinopathies. Its product candidate, IMR-687 is a highly selective and small molecule inhibitor of PDE9. The company was founded by James G. McArthur in 2016 and is headquartered in Cambridge, MA.

Head office	United States
CEO	Samuel Kintz
Employees	62
Founded	2019
Website	www.enliventherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now